Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Letairis, Volibris
Ambrisentan is a selective endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries of the lungs. It specifically targets the endothelin A receptor, which plays a role in vasoconstriction and vascular remodeling in PAH. By blocking this receptor, ambrisentan helps to dilate the pulmonary arteries and reduce vascular resistance, improving blood flow and symptoms in patients with PAH.
For the treatment of pulmonary arterial hypertension (PAH).
Ambrisentan can cause severe liver injury, including liver failure and death. Liver function tests should be performed before starting treatment and monthly thereafter. Ambrisentan is also teratogenic and should not be used in pregnant women.
Outcome:
Increased ambrisentan levels
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Increased digoxin levels
Mechanism:
Unknown
Outcome:
Decreased ambrisentan absorption
Mechanism:
Chelation
Most likely new formulation: extended-release ambrisentan (Year 2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 75% likelihood of ambrisentan maintaining its current FDA approval status for PAH.
Endothelin Receptor Antagonist
Propanoic acid derivative